Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-ibritumomab tiuxetan after first-line R-CHOP in PET-positive partial remission DLBCL
2005-003796-20Phase 2Completed
- Sponsor
- HOVON
- Start
- Dec 2006
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL), sponsored by HOVON. Primary endpoint: Complete response on FDG-PET. Started Dec 2006; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2005-003796-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003796-20.